WCLC 2025 | The current state of ADC biomarker testing in India

So I’m from India and this is a newer area for us wherein we don’t have a very highly developed system for biomarker testing for ADCs. So for our nation it’s just evolving. I in particular make sure to test for those biomarkers that are directing application to very nuanced therapies, novel therapies, and that’s where we are testing for different malignancies for different biomarkers. For example, the IHC-based testing for HER2 is a routine now, and especially because a lot of us also treat breast cancer, you know, knowing what is IHC3+, what is low, what is ultra low, and wherein you would apply T-DM1 has also already come in. Of course, in a lung case, we would look for mutations, so HER2 mutations. We are also doing Nectin-4, Trop2. We are doing for our one receptor we are doing. So a lot of these receptors are getting looked at, mainly because there is direct application. So for Zolbetuximab, we also are going to be testing. So we routinely review the case and look at an entire panel of ADC biomarkers that are already available in the country. and at the precision center, at my precision center, actually we are not even organ specific. We are in a discovery mode. So we test all our patients with all the biomarkers that we have in the stack, five, six biomarkers that we are testing for ADC’s application.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.